finance.yahoo.comNov 10$DFTX

Definium (DFTX) Q3 2026 Earnings Call Transcript

Definium (DFTX) reported Q3 2026 earnings, highlighting FDA breakthrough therapy designations for DT120. The company plans an NDA filing in H1 2027 and shared positive clinical data for DT120 and DT402. DT120 showed significant improvements in anxiety and depression trials, with plans to expand into PTSD. DT402 showed early promise in autism spectrum disorder studies. The company is preparing for a potential launch, focusing on commercial infrastructure and provider engagement.

Original reporting

finance.yahoo.com

Published Nov 10, 2026, 2:00 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 10, 2026, 2:10 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Definium (DFTX) Q3 2026 Earnings Call Transcript — source image — Source · finance.yahoo.com

Decision brief

The 30-second read

$DFTXBullishMed

Why it matters

The announcements provide fresh, material information that could influence the stock price and sector sentiment.

Market read

First disclosure of FDA breakthrough designations and early autism trial data may drive short‑term buying interest.

What to watch

Regulatory timelines and reimbursement uncertainties could delay commercial rollout despite breakthrough designations.

Relevance 8/10Novelty 8/10Timing: immediate, as the announcements were made during the Q3 2026 earnings call

Background

Definium (DFTX) held its Q3 2026 earnings call, focusing on clinical updates for its DT120 and DT402 programs.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$DFTXBullishHigh confidence

Context

Definium disclosed two FDA breakthrough therapy designations for DT120 and presented initial Phase 2a results for DT402 in autism, indicating significant clinical progress.

Expected impact

likely upward pressure as investors price in the breakthrough designations and encouraging early-stage data.

Evidence & confidence

First public disclosure of FDA designations and new trial results provides fresh material that can move the share price.

Market effects

Sector

strengthens the biotech sector's pipeline outlook, especially for companies developing rapid‑onset psychiatric therapies.

Regional

potentially boosts US biotech sentiment, with limited immediate effect on other regions.

Global

adds to global interest in breakthrough psychiatric treatments, but impact is primarily US‑centric.

Counterpoint

What could challenge this read

The data are early‑stage and sample sizes are small; investors may remain cautious until larger Phase 3 results are available.

Key entities

Company
Definium
Biotech firm developing rapid‑onset psychiatric treatments.

Read at source ← All news

$DFTXMed

What Definium Therapeutics (DFTX) Said on Its Q3 Earnings Call

Definium Therapeutics (DFTX) reported Q3 earnings, highlighting progress in clinical trials for DT120 and DT402. DT120 showed tolerability in Phase 3 studies, with top-line results for Ascend expected in 2027. DT402's early autism study was halted after five participants showed consistent efficacy signals. R&D expenses rose to $46.1M, with a net loss of $51M, narrower than the previous year. The company plans commercial preparations for DT120, targeting a pricing range of $30,000-$75,000.

finance.yahoo.comNov 10

$DFTXHighAI 8/10

Why is Definium Therapeutics stock gaining today?

Definium Therapeutics (DFTX) shares rose 0.2% after reporting Q3 2026 results. The company narrowed its net loss to $50.96M, reported positive Phase 3 results for DT120 ODT in anxiety, and received FDA Breakthrough Therapy Designation for depression. Cash reserves increased to $1.05B. Analysts maintain a Buy consensus with raised price targets.

investing.comNov 9

$DFTXHighAI 9/10

Definium Therapeutics Reports $51.0 Million Q3 Net Loss and DT120 Phase 3 Progress

Definium Therapeutics reported a Q3 2026 net loss of $51.0M, down from $67.3M a year prior, with $1.05B in cash. DT120 ODT showed positive Phase 3 results for GAD and received FDA Breakthrough Therapy Designation for MDD. The company plans to file an NDA for DT120 ODT in H1 2027.

tradingview.comNov 9

$DFTXHigh

Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent

Definium Therapeutics, Inc. (DFTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights Reported positive topline Phase 3 results from two Phase 3 studies of DT120 ODT in generalized anxiety disorder (GAD) Received FDA Breakthrough Therapy Designation for DT120 ODT

SEC EDGAR 8-KNov 9

$DFTXHighAI 9/10

Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress

Definium Therapeutics (DFTX) will present positive topline data from three Phase 3 studies of DT120 ODT for generalized anxiety disorder (GAD) and major depressive disorder (MDD) at the 2026 NEI Fall Congress. The studies, Panorama, Emerge, and Voyage, showed efficacy and safety, with DT120 ODT receiving FDA Breakthrough Therapy designation for GAD and MDD. The presentations will include comprehensive safety data and support continued clinical assessment.

standard-freeholder.comNov 4

$DFTXMedAI 8/10

RBC Capital reiterates Definium Therapeutics stock rating on strong trial data

RBC Capital reiterated an Outperform rating for Definium Therapeutics (DFTX) with a $66 price target, citing strong Phase III trial data for anxiety and depression treatments. Despite a 30% share price drop, RBC sees potential for approval and $2.5B peak revenue. Other analysts also raised price targets following positive trial results.

investing.comOct 19